Lucentis® (Ranibizumab) approved for the treatment of "wet" macular degeneration
A new drug, Lucentis®, was approved for the treatment of the "wet" form of macular degeneration on June 30, 2006. Drs. Sjaarda and Thompson are very experienced in the use of Lucentis® as they have participated in clinical studies of this drug for the past 4 years leading to FDA approval. Lucentis® is injected into the vitreous humor of the eye at approximately monthly intervals and has a greater probability of improving vision compared to prior therapies. The drug works best in patients who have recently developed new blood vessels from macular degeneration. Drs. Sjaarda and Thompson have extensive experience in the use of other pharmacologic treatments for macular degeneration including Visudyne® and Macugen® and Avastin®. They can help determine which therapy will be most appropriate for an individual.
Since our beginning, we have been on the cutting edge of advances in treating some very common eye conditions. We have been involved in clinical trials that have led to approval of three major treatments for wet age-related macular degeneration, and we are now enrolling or will soon begin to enroll patients in three more studies.
Below is a list of all the studies which Retina Specialists are participating or have participated at Retina Specialists. Please call our office at 410-296-9700 for more information.
CURRENT CLINICAL STUDIES:
Age-related Macular Degeneration (Dry-Geographic Atrophy)
Age Related Macular Degeneration (Wet-Neovascularization)
|VIEW1/Regeneron Extension||Phase II||Follow-Up|
PREVIOUS CLINICAL TRIALS:
|CATT/National Eye Institute||Comparative Trial|
|LEVEL/OSI – EyeTech||Phase IV|
|GENAERA 208/209||Phase II|
|GENAERA 301||Phase III|
|PKC (MBDV)/Eli Lilly||Open Label|
|PKC (MBCM)/Eli Lilly||Phase III|
Nonclearing Vitreous Hemorrhage
|Hyaluronidase/Advanced Corneal||Phase III|
|Hyaluronidase/Advanced Corneal||Phase II – Closed|
Retinal Vein Occlusions
|Posurdex Study/Allergan||Phase III|
Click on this link for more information, and please contact our office at 410-296-9700 if you are interested in learning more about the latest clinical studies.